# Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

> **NCT06429449** · PHASE1 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 30 (estimated)

## Conditions studied

- Leukemia
- Myeloid Leukemia
- Monocytic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT06429449
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-21
- **Primary completion:** 2026-12
- **Final completion:** 2027-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429449, "Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06429449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*